Connexin Genotypes in Cystic Fibrosis
Impact of Connexin 37, Connexin 43 on Clinical Disease Phenotype in Delta F508 Homozygous Patients With Cystic Fibrosis (CF) (CF-Modifier)
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
This NA trial investigates Cystic Fibrosis and Inflammation and is currently ongoing. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) leads this study, which shows 9 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Mar 2023 — Jul 2024 [monthly]
Recruiting NA
-
Apr 2022 — Mar 2023 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2020 — Dec 2020 [monthly]
Recruiting NA
First recorded
Apr 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Goethe University
- University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
For direct contact, visit the study record on ClinicalTrials.gov .